Effects of sub-chronic, in vivo administration of sigma-1 receptor ligands on platelet and aortic arachidonate cascade in streptozotocin-induced diabetic rats

PLoS One. 2022 Nov 17;17(11):e0265854. doi: 10.1371/journal.pone.0265854. eCollection 2022.

Abstract

Background: Diabetes mellitus is a chronic metabolic disorder which induces endothelial dysfunction and platelet activation. Eicosanoids produced from arachidonic acid regulate cellular and vascular functions. Sigma-1 receptors (S1R) are expressed in platelets and endothelial cells and S1R expression is protective in diabetes.

Objectives: Our aim was to examine the influence of sub-chronic, in vivo administered S1R ligands PRE-084, (S)-L1 (a new compound) and NE-100 on the ex vivo arachidonic acid metabolism of platelets and aorta in streptozotocin-induced diabetic rats.

Methods: The serum level of the S1R ligands was detected by LC-MS/MS before the ex vivo analysis. Sigma-1 receptor and cyclooxygenase gene expression in platelets were determined by RT-qPCR. The eicosanoid synthesis was examined with a radiolabelled arachidonic acid substrate and ELISA.

Results: One month after the onset of STZ-induced diabetes, in vehicle-treated, diabetic rat platelet TxB2 and aortic 6-k-PGF1α production dropped. Sub-chronic in vivo treatment of STZ-induced diabetes in rats for one week with PRE-084 enhanced vasoconstrictor and platelet aggregator and reduced vasodilator and anti-aggregator cyclooxygenase product formation. (S)-L1 reduced the synthesis of vasodilator and anti-aggregator cyclooxygenase metabolites and promoted the recovery of physiological platelet function in diabetic rats. The S1R antagonist NE-100 produced no significant changes in platelet arachidonic acid metabolism. (S)-L1 decreased the synthesis of vasoconstrictor and platelet aggregator cyclooxygenase metabolites, whereas NE-100 increased the quantity of aortic vasodilator and anti-aggregator cyclooxygenase products and promoted the recovery of diabetic endothelial dysfunction in the aorta. The novel S1R ligand, (S)-L1 had similar effects on eicosanoid synthesis in platelets as the agonist PRE-084 and in aortas as the antagonist NE-100.

Conclusions: S1R ligands regulate cellular functions and local blood circulation by influencing arachidonic acid metabolism. In diabetes mellitus, the cell-specific effects of S1R ligands have a compensatory role and aid in restoring physiological balance between the platelet and vessel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / metabolism
  • Arachidonic Acid / pharmacology
  • Arachidonic Acids / metabolism
  • Chromatography, Liquid
  • Cyclooxygenase 2
  • Diabetes Mellitus, Experimental* / metabolism
  • Eicosanoids
  • Endothelial Cells / metabolism
  • Ligands
  • Rats
  • Sigma-1 Receptor
  • Streptozocin
  • Tandem Mass Spectrometry
  • Vasoconstrictor Agents
  • Vasodilator Agents

Substances

  • Streptozocin
  • N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride
  • Arachidonic Acid
  • Ligands
  • Arachidonic Acids
  • Eicosanoids
  • Cyclooxygenase 2
  • Vasodilator Agents
  • Vasoconstrictor Agents

Grants and funding

Funding: This work was funded by the National Research, Development and Innovation Office of Hungary, grant number GINOP-2.3.2-15-2016-00060, by the EU-funded Hungarian grant EFOP-3.6.2-16-2017-00006, Gedeon Richter Plc. Centenarial Foundation, grant number: 2020/K/21/2503. S.V. was supported by a scholarship from Gedeon Richter’s Talentum Foundation (1103 Budapest, Gyömrői út 19-21.). L.B. was supported by the ÚNKP-20-3-SZTE-503 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund.